Skip to main content
. 2021 Jul 29;61(7):1102–1111. doi: 10.1111/head.14178

FIGURE 2.

FIGURE 2

Changes from baseline in the monthly (28‐day) average number of migraine days (full analysis set population). An asterisk denotes p < 0.0001 for the comparison of fremanezumab monthly or quarterly with placebo; mixed‐effects model for repeated measures (MMRM) analysis. A dagger denotes p < 0.0001 for the comparison of fremanezumab monthly or quarterly with placebo; primary endpoint